CORRECTION

CrossMark

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

J. A. Walsh[1] · A. B. Gottlieb[2] · B. Hoepken[3] · T. Nurminen[3] · P. J. Mease[4]

Correction to: Clinical Rheumatology.
https://doi.org/10.1007/s10067-018-4227-7

The publisher regret that the above article was originally published with an error present in the Discussion section "As of August 2018, CZP is the only biologic with clinical trial data in its label supporting potential use in both pregnancy and breastfeeding in chronic rheumatic diseases (axSpA, PsA, RA), as indicated in the CZP SmPC [10, 34, 36]. **cavailable in the published literature, further information in this area will be of great importance moving forward, particularly regarding the use of biologics as monotherapies**." This should instead have read

"As of August 2018, CZP is the only biologic with clinical trial data in its label supporting potential use in both pregnancy and breastfeeding in chronic rheumatic diseases (axSpA, PsA, RA), as indicated in the CZP SmPC [10, 34, 36]. **Given the paucity of data currently available in the published literature, further information in this area will be of great importance moving forward, particularly regarding the use of biologics as monotherapies**." [Bold text has been used to highlight the problem area].

The original article was corrected.

The online version of the original article can be found at https://doi.org/10.1007/s10067-018-4227-7

✉ J. A. Walsh
  jessica.walsh@hsc.utah.edu

1 Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, USA

2 Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, USA

3 UCB Pharma, Monheim, Germany

4 Swedish Medical Center and University of Washington, Seattle, WA, USA